Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR

Pharmacology Research and Perspectives

Volumn 3, Issue 4, 2015, Pages

  Farinha, Carlos M ^a   Sousa, Marisa ^a,b   Canato, Sara ^a   Schmidt, André ^a,c   Uliyakina, Inna ^a   Amaral, Margarida D ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b NOVA MEDICAL SCHOOL   (Portugal)

^c PROQR THERAPEUTICS   (Netherlands)

Author keywords

Cellular systems; CFTR function; CFTR modulators; mechanism of action; novel therapies

Indexed keywords

LUMACAFTOR;

ANALYSIS OF VARIANCE; ANIMAL CELL; ARTICLE; BIOGENESIS; CELL MEMBRANE; CELL MEMBRANE CONDUCTANCE; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG STABILITY; ELECTRIC RESISTANCE; EPITHELIUM CELL; GENE MUTATION; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84969374206     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.152     Document Type: Article

References (45)

1. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. (2010). Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363: 1991–2003.
2. Amaral MD (2004). CFTR and chaperones: processing and degradation. J Mol Neurosci 23: 41–48.
3. Amaral MD, Farinha CM (2013). Rescuing mutant CFTR: a multi-task approach to a better outcome in treating cystic fibrosis. Curr Pharm Des 19: 3497–3508.
4. Balch WE, Roth DM, Hutt DM (2011). Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb Perspect Biol 3: a004499.
5. Bebok Z, Collawn JF, Wakefield J, Parker W, Li Y, Varga K, et al. (2005). Failure of cAMP agonists to activate rescued deltaF508 CFTR in CFBE41o- airway epithelial monolayers. J Physiol 569: 601–615.
6. Beekman JM, Sermet-Gaudelus I, de Boeck K, Gonska T, Derichs N, Mall MA, et al. (2014). CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy: report on the pre-conference meeting to the 11th ECFS Basic Science Conference, Malta, 26-29 March 2014. J Cyst Fibros 13: 363–372.
7. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, et al. (2014). A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2: 527–538.
8. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, et al. (1990). Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63: 827–834.
9. Cholon DM, Quinney NL, Fulcher ML, Esther CR Jr, Das J, Dokholyan NV, et al. (2014). Potentiator ivacaftor abrogates pharmacological correction of DeltaF508 CFTR in cystic fibrosis. Sci Transl Med 6: 246ra296.
10. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, et al. (2012). Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67: 12–18.
11. Collins FS (1992). Cystic fibrosis: molecular biology and therapeutic implications. Science 256: 774–779.
12. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ (1992). Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358: 761–764.
13. Eckford PD, Ramjeesingh M, Molinski S, Pasyk S, Dekkers JF, Li C, et al. (2014). VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface. Chem Biol 21: 666–678.
14. Farinha CM, Amaral MD (2005). Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. Mol Cell Biol 25: 5242–5252.
15. Farinha CM, Nogueira P, Mendes F, Penque D, Amaral MD (2002). The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70. Biochem J 366: 797–806.
16. Farinha CM, Mendes F, Roxo-Rosa M, Penque D, Amaral MD (2004). A comparison of 14 antibodies for the biochemical detection of the cystic fibrosis transmembrane conductance regulator protein. Mol Cell Probes 18: 235–242.
17. Farinha CM, King-Underwood J, Sousa M, Correia AR, Henriques BJ, Roxo-Rosa M, et al. (2013). Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. Chem Biol 20: 943–955.
18. He L, Kota P, Aleksandrov AA, Cui L, Jensen T, Dokholyan NV, et al. (2013). Correctors of {Delta}F508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J 27: 536–545.
19. Jensen TJ, Loo MA, Pind S, Williams DB, Goldberg AL, Riordan JR (1995). Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83: 129–135.
20. Kim Chiaw P, Wellhauser L, Huan LJ, Ramjeesingh M, Bear CE (2010). A chemical corrector modifies the channel function of F508del-CFTR. Mol Pharmacol 78: 411–418.
21. Lansdell KA, Kidd JF, Delaney SJ, Wainwright BJ, Sheppard DN (1998). Regulation of murine cystic fibrosis transmembrane conductance regulator Cl- channels expressed in Chinese hamster ovary cells. J Physiol (Lon) 512: 751–764.
22. Loo TW, Bartlett MC, Clarke DM (2009). Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule. Biochemistry 48: 9882–9890.
23. Loo TW, Bartlett MC, Wang Y, Clarke DM (2006). The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants. Biochem J 395: 537–542.
24. Moniz S, Sousa M, Moraes BJ, Mendes AI, Palma M, Barreto C, et al. (2013). HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR. ACS Chem Biol 8: 432–442.
25. Okiyoneda T, Veit G, Dekkers JF, Bagdany M, Soya N, Xu H, et al. (2013). Mechanism-based corrector combination restores DeltaF508-CFTR folding and function. Nat Chem Biol 9: 444–454.
26. Pedemonte N, Tomati V, Sondo E, Galietta LJ (2010). Influence of cell background on pharmacological rescue of mutant CFTR. Am J Physiol Cell Physiol 298: C866–C874.
27. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJ, et al. (2005a). Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 115: 2564–2571.
28. Pedemonte N, Sonawane ND, Taddei A, Hu J, Zegarra-Moran O, Suen YF, et al. (2005b). Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 67: 1797–1807.
29. Ren HY, Grove DE, De La Rosa O, Houck SA, Sopha P, Van Goor F, et al. (2013). VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell 24: 3016–3024.
30. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066–1073.
31. Rowe SM, Pyle LC, Jurkevante A, Varga K, Collawn J, Sloane PA, et al. (2010). DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. Pulm Pharmacol Ther 23: 268–278.
32. Roxo-Rosa M, Xu Z, Schmidt A, Neto M, Cai Z, Soares CM, et al. (2006). Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms. Proc Natl Acad Sci USA 103: 17891–17896.
33. Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR (1996). Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 271: 635–638.
34. Schultz BD, Frizzell RA, Bridges RJ (1999). Rescue of dysfunctional deltaF508-CFTR chloride channel activity by IBMX. J Membr Biol 170: 51–66.
35. Sharma M, Pampinella F, Nemes C, Benharouga M, So J, Du K, et al. (2004). Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J Cell Biol 164: 923–933.
36. Swiatecka-Urban A, Brown A, Moreau-Marquis S, Renuka J, Coutermarsh B, Barnaby R, et al. (2005). The short apical membrane half-life of rescued {Delta}F508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of {Delta}F508-CFTR in polarized human airway epithelial cells. J Biol Chem 280: 36762–36772.
37. Tian Y, Schreiber R, Wanitchakool P, Kongsuphol P, Sousa M, Uliyakina I, et al. (2013). Control of TMEM16A by INO-4995 and other inositolphosphates. Br J Pharmacol 168: 253–265.
38. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, et al. (2011). Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 108: 18843–18848.
39. Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, et al. (2006). Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290: L1117–L1130.
40. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, et al. (2009). Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 106: 18825–18830.
41. Veit G, Avramescu RG, Perdomo D, Phuan PW, Bagdany M, Apaja PM, et al. (2014). Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression. Sci Transl Med 6: 246ra297.
42. VERTEX (2014). Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation. Available at http://investors.vrtx.com/releasedetail.cfm?ReleaseID=856185 (Accessed 27 January 2015).
43. Wang Y, Bartlett MC, Loo TW, Clarke DM (2006). Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Mol Pharmacol 70: 297–302.
44. Wang Y, Loo TW, Bartlett MC, Clarke DM (2007a). Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants. Biochem J 406: 257–263.
45. Wang Y, Loo TW, Bartlett MC, Clarke DM (2007b). Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones. Mol Pharmacol 71: 751–758.